Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

Key highlights

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Showing: 1 – 05 of 158 Press Releases

Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director

PARIS, FRANCE, 4 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Pascal Touchon to its Board as an independent director, effective 4 October 2023, following the decision of Paul Sekhri to step down from his director…


Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet

 PARIS, FRANCE, 1 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Christelle Huguet as Executive Vice President, Head of Research and Development. She will succeed Howard Mayer, EVP and Head…


Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer 


US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification in…


Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confident, as…


1 2 3 4 32

Your dedicated contacts